Verastem sets Oct. 14 investor event to present new VS-7375 KRAS G12D trial data across solid tumors
VSTM•Investor event scheduled for Oct. 14
Verastem scheduled an investor webcast for Oct. 14, 2026 to present new clinical data for VS-7375 in KRAS G12D cancers.
Results will be presented in the future, with initial efficacy and updated safety and tolerability from the ongoing TARGET-D program.
Management framed VS-7375 as a potential best-in-class oral inhibitor, targeting pancreatic, lung, and colorectal tumors.
The update builds on clinical findings already presented in June 2026, moving toward a broader cross-tumor assessment.
